# Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

> **NCT00514020** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **GENETIC:** gene expression analysis
- **GENETIC:** polymorphism analysis
- **GENETIC:** protein expression analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00514020
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2012-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514020, "Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00514020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*